To the best of our knowledge, this is the first study to evaluate the potential of Ang-1 as a biomarker in patients with different PH subtypes (iPAH, CTD-PAH, PH-LHD, and CTEPH). This evidence concerns the gene ANGPT1 and chronic thromboembolic pulmonary hypertension.